SL 340026
Alternative Names: SL 34002600Latest Information Update: 04 Oct 2001
At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 04 Oct 2001 No-Development-Reported for Alzheimer's disease in France (Unknown route)
- 04 Oct 2001 No-Development-Reported for Parkinson's disease in France (Unknown route)
- 27 Aug 1999 Sanofi and Synthélabo have now merged to form Sanofi-Synthélabo